Outcome of allogeneic stem cell transplantation following reduced-intensity conditioninig regimen in patients with idiopathic myelofibrosis: The G.I.T.M.O. Experience

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 2, Issue 2, 2010, Pages

  Patriarca, Francesca ^a   Bacigalupo, Andrea ^b   Sperotto, Alessandra ^a   Isola, Miriam ^a   Bruno, Barbara ^b   van Lint, Maria Teresa ^b   Iori, Anna Paola ^c   Di Bartolomeo, Paolo ^d   Musso, Maurizio ^e   Pioltelli, Pietro ^f   Visani, Giuseppe ^g   Iacopino, Pasquale ^h   Fanin, Renato ^a   Bosi, Alberto ⁱ  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Pescara Hospital   (Italy)

^e LA MADDALENA CANCER CENTER   (Italy)

^f Internal Medicine and Hematology Division   (Italy)

^g SAN SALVATORE HOSPITAL   (Italy)

^h Reggio Calabria Hospital   (Italy)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; THIOTEPA;

ALLOGENEIC STEM CELL TRANSPLANTATION; BLAST CELL; CLINICAL FEATURE; DONOR; DUPRIEZ SCORE; EVENT FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; ITALY; LEUKOCYTE COUNT; MORTALITY; MULTICENTER STUDY (TOPIC); MYELOFIBROSIS; PROGNOSIS; REDUCED INTENSITY CONDITIONING; RELAPSE; REVIEW; SCORING SYSTEM; SIBLING; SURVIVAL; TREATMENT OUTCOME;

EID: 79952774392     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2010.010     Document Type: Review

References (29)

1. Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system Blood 1996, 88: 1013-1018.
2. Elliott MA, Verstovsek S, Dingli D, Schwager SM, Mesa RA, Li Cy, Tefferi A. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis Leuk Res 2007; 31: 1503-1509.
3. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. A new prognostic scoring system for primary myelofibrosis based on a study of the international Working Group for Myelofibrosys Research and Treatment. Blood 2009; 113: 2895-2901.
4. Guardiola P, Anderson JE, Bandini G et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Sociètè Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto di Midollo Osseo and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999, 93: 2831-2838.
5. Deeg HJ, Gooley TA, Flowers ME et al. Allogeneic hematopietic stem cell transplantation for myelofibrosis. Blood 2003, 102:3912-3918.
6. Kerbauy DMB, Gooley TA, Sale GE et al Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera and essential trombocythemia. Biol Blood Marrow Transplant 2007, 13:355-365.
7. Guardiola P, Anderson EA, Gluckman E. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000, 343:659-660.
8. Daly A, Song K, Nevill T et al. Stem cell transplantation for myelofibrosis: a report from two Canadian centers. Bone Marrow Transplant 2003,32: 35-40.
9. Ditschkowski M, Beelen DW, Trenschel R et al. Outcome of allogeneic stem cell transplantation in patients with myelofibrosis. Bone Marrow Transplant 2004, 34: 807-813.
10. Rondelli D, Barosi G, Bacigalupo A, et al Allogeneic hematopoietic stem-cell transplantation with reducedintensity conditioning in intermediateor high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005, 105: 4115-4119.
11. Kroger N, Zabelina T, Schieder H et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Hematol 2005, 128: 690-697.
12. Snyder DS, Palmer J, Stein AS et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 2006, 12: 1161-1168.
13. Devine SM, Hoffman R, Verma A et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002, 99: 2255-2258.
14. Merup M, Lazarevic V, Nahi H et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Hematol 2006, 135: 367-373.
15. Patriarca F, Bacigalupo A, Sperotto A, et al., on benhalf of GITMO. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the twenty-year experience of GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Hematologica 2008; 93: 1514-1522.
16. Eder PE, Antman K, Elias A et al. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst, 1988: 1221-1226.
17. Aversa F, Tabilio A, Terenzi A et al Successful engraftment of T-cell-depleted haploidentical 'three-loci' incompatible transplants in leukaemia patients by addition of recombinant human granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994, 84: 3948-3955.
18. Rosales F, Naparstek E, Varadi G et al. The role of thiotepa in allogeneic stem cell transplantation in patients with leukaemia. Leuk Res 1999, 23: 947-952.
19. Bacigalupo A, Van Lint MT, Valbonesi M et al. Thiotepacyclophosphamide followed by granulocyte colonystimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukaemia. Blood 1998, 88: 353-357.
20. Raiola AM, Van Lint MT, Lamparelli T at al. Reducedintensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Hematol 2000, 109: 716-721.
21. Corradini P, Dodero A, Farina L et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007, 21: 2316-2323.
22. Alessandrino EP, Della Porta GM, Bacigalupo A, et al.. WHO classification and WPSS predict posttransplantation outcome in patients with myelodisplastyc syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Blood 2008; 112: 895-902.
23. Kroger N, Holler E, Kobbe G, et al.. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with myelofibrosis: a multicenter prospective study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Blood 2009, 114: 5264-5270.
24. Kroger N, Badbaran A, Holler E et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative realtime PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007, 109: 1316-1321.
25. Kroger N, Thiele J, Zander A, et al. on behalf of of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with myelofibrosis. Experimental Hematology 2007; 35: 1719-1722.
26. Bacigalupo A., Soraru M, Dominietto A, et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type Bone Marrow Transplantation 2009, 1-6.
27. Li Z, Deeg HJ. Splenectomy and transplantation for myelofibrosis. Leukemia 2001; 15: 465-467.
28. Li Z, Gooley T, Applebaum FR, Deeg HJ. Splenectomy and hematopoietic stem cell transplantation in myelofibrosis. Blood 2001; 97:2180-2181
29. Mesa RA, Nagorney DS, Schwanger S et al. palliative goals, patient selection, and perioperative platelet management: outcome and lessons from 3 decades of splectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107:361-370.